Lilly(US:LLY) The Motley Foolยท2025-10-15 00:05Core Viewpoint - Eli Lilly is considered one of the top stocks in the healthcare sector to buy, despite facing some challenges this year, due to its strong market performance and innovative product pipeline [1]. Innovation - Eli Lilly has demonstrated significant innovation, particularly with the launch of tirzepatide, which is marketed as Mounjaro for diabetes and Zepbound for obesity, representing a breakthrough as the first dual GLP-1 and GIP agonist [2]. - Tirzepatide has shown to be more effective than traditional GLP-1 drugs, achieving unprecedented sales figures, projected to exceed $20 billion in its third full year on the market [3]. Future Prospects - The approval of Kisunla for Alzheimer's disease marks a significant expansion of Eli Lilly's innovative capabilities beyond its core markets, indicating a strong future potential [4]. - The company has expanded its pipeline through acquisitions and licensing deals, which is expected to drive clinical and regulatory success, leading to strong financial results into the next decade [5].